Terumo Corp. (OTCMKTS:TRUMY) Short Interest Update

Terumo Corp. (OTCMKTS:TRUMYGet Free Report) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 30,823 shares, a decline of 91.6% from the April 15th total of 367,048 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 350,364 shares, the short-interest ratio is currently 0.1 days.

Terumo Price Performance

Terumo stock opened at $12.39 on Tuesday. Terumo has a 52-week low of $12.15 and a 52-week high of $20.12. The firm has a fifty day moving average of $13.13 and a 200-day moving average of $14.10. The firm has a market capitalization of $18.28 billion, a P/E ratio of 21.37 and a beta of 0.62. The company has a quick ratio of 0.89, a current ratio of 1.51 and a debt-to-equity ratio of 0.07.

Terumo (OTCMKTS:TRUMYGet Free Report) last released its quarterly earnings data on Friday, February 13th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Terumo had a return on equity of 9.01% and a net margin of 11.74%.The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.82 billion. As a group, analysts predict that Terumo will post 0.58 EPS for the current year.

Analyst Upgrades and Downgrades

TRUMY has been the subject of a number of research analyst reports. Zacks Research raised shares of Terumo to a “hold” rating in a research report on Thursday, April 9th. Nomura raised shares of Terumo to a “hold” rating in a research report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

View Our Latest Analysis on TRUMY

About Terumo

(Get Free Report)

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

Featured Stories

Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.